Presentation on Wednesday, January 11, 2017, at 5:00 p.m. Pacific Time
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 4, 2017--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will
present a company overview at the 35th Annual J.P. Morgan Healthcare
Conference in San Francisco on Wednesday, January 11, 2017, at 5:00 p.m.
A live audio webcast of the presentation and breakout session will be
accessible from the Investor Relations section of the Aimmune website at www.aimmune.com.
A replay of the webcast will be available at www.aimmune.com
for up to 90 days following the event.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational product using CODIT™, AR101
for the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials in ages 4-55. AR101 is a characterized, regulated, oral
biological drug product containing the protein profile found in peanuts.
For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005451/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,